Together, these results provide convincing evidence that ILF3 is a transcriptional activator of MRPL12 expression and sorafenib triggered ILF3‐MRPL12 axis confers HCC cells drug resistance. This evidence concerns the gene ILF3 and hepatocellular carcinoma.